**Market-implied odds for major company IPOs before year-end 2027 reflect a selective window shaped by strong 2026 issuance momentum offset by rate volatility and election timing.** Global equity issuance rose sharply earlier in the year, with U.S. volumes exceeding prior periods and Hong Kong on pace for a record near HK$500 billion, led by A+H and specialist tech listings. SpaceX’s large June listing and ongoing biotech and AI-adjacent filings demonstrate reopened access for scaled names, yet OpenAI has shifted to 2027 while Anthropic targets a November U.S. debut ahead of midterms. Recent Fed rate action, elevated Treasury yields, and scrutiny of AI spending have kept investor selectivity high, with deal flow now concentrated in high-quality issuers showing durable fundamentals. Traders price near-term catalysts around Q4 filings, post-election stability, and aftermarket performance of recent listings as key swing factors for additional 2026 resolutions.